The Nevada Cannabis Compliance Board (CCB) has opened an investigation into several dispensaries for allegedly selling tainted marijuana products, the agency announced Tuesday.
In a news release, the CCB, which governs the Silver State’s cannabis industry, said marijuana strain Cherry OG F3 twice failed microbial testing earlier this year. However, three Las Vegas retail shops continued to sell through inventory despite a March 5, 2020 CCB directive to halt sales.
According to the agency, Nevada dispensaries were instructed to “destroy or return the affected product to the cultivator” and inform the state of their removal.
However, it appears three companies — Waveseer of Las Vegas, LLC (Jenny’s Dispensary), Paradise Wellness Center, LLC (Las Vegas ReLeaf) and Desert Aire Wellness, LLC (Sahara Wellness) — disregarded the CCB’s mandate and continued selling the compromised product anyway.
According to the CCB, roughly 375 grams the Cherry OG F3 products in question were sold between May 19, 2020 and June 29, 2020. They had previously failed lab tests for yeast and mold, coliforms, Enterobacteriaceae and Aspergillus.
Enterobacteriaceae is a family of bacteria that includes salmonella and E.coli, and can cause infections such as pneumonia.
Aspergillus is a fungus that is commonly spread through the air we breathe but can pose serious risks to immunocompromised individuals — especially those consuming cannabis for medical reasons.
“The CCB advises those who have purchased the product to avoid consuming it,” the agency wrote.
This isn’t the first time state officials have had to crack down on cannabis companies for selling contaminated products. Earlier this year, the Nevada Department of Taxation sent out a public health and safety advisory informing cannabis consumers to avoid using several products sold at more than two dozen dispensaries.
Issued on February 21, 2020, the advisory listed 20 products that failed testing for yeast,